| Literature DB >> 36248805 |
Yue Zhang1,2,3, Wenzhi Hu2, Dongbo Chen4, Ming Ding2, Tao Wang2, Yaojun Wang2, Jiaoni Chi2, Zhimin Li2, Qiang Li2, Chengxin Li1,3.
Abstract
Artemisia pollen is the major cause of seasonal allergic respiratory diseases in the northern hemisphere. About 28.57% of Artemisia allergic patients' IgE can recognize ArtCaM, a novel allergenic calmodulin from Artemisia identified in this study. These patients exhibited stronger allergic reactions and a longer duration of allergic symptoms. However, the signaling mechanism that triggers these allergic reactions is not fully understood. In this study, we found that extracellular ArtCaM directly induces the maturation of human dendritic cells (DCs), which is attributed to a series of Ca2+ relevant cascades, including Ca2+/NFAT/CaMKs. ArtCaM alone induces inflammatory response toward Th1, Th17, and Treg. Interestingly, a combination of ArtCaM and anti-ArtCaM IgE led to Th2 polarization. The putative mechanism is that anti-ArtCaM IgE partially blocks the ArtCaM-induced ERK signal, but does not affect Ca2+-dependent cascades. The crosstalk between ERK and Ca2+ signal primes DCs maturation and Th2 polarization. In summary, ArtCaM related to clinical symptoms when combined with anti-ArtCaM IgE, could be a novel allergen to activate DCs and promote Th2 polarization. Such findings provide mechanistic insights into Th2 polarization in allergic sensitization and pave the way for novel preventive and therapeutic strategies for efficient management of such pollen allergic disease.Entities:
Keywords: Artemisia pollen; Th2; allergy (hypersensitive anaphylaxis); calmodulin; dendritic cell
Mesh:
Substances:
Year: 2022 PMID: 36248805 PMCID: PMC9556433 DOI: 10.3389/fimmu.2022.996427
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Chinese patients information (n=77), age, gender, allergy symptoms, allergy symptoms, total IgE levels, specific IgE (for A.vulgaris), skin prick testing (SPT), onset time of allergic symptoms and immunoblot results.
| PatientID | Age | Gender | Symptomsa | tIgEb(IU/ml) | sIgEc(IU/ml) | SPTd | Onset timee | IBf |
|---|---|---|---|---|---|---|---|---|
| 1 | 26 | M | R | >500 | >200 | ++ | Jul. | – |
| 2 | 58 | F | C,R,D | >500 | >200 | ++++ | Oct. | + |
| 3 | 30 | M | R | >500 | >200 | ++++ | Jul. | + |
| 4 | 38 | F | C,R | >500 | >200 | +++ | Jul. | + |
| 5 | 30 | M | AS,C,R | >500 | >200 | ++++ | Jun. | + |
| 6 | 29 | F | R | >500 | >200 | ++++ | AYR | + |
| 7 | 26 | M | C,R | >500 | 8.25 | ++ | Aug. | – |
| 8 | 35 | F | C,R | 203.77 | 16.05 | ++++ | AYR | + |
| 9 | 24 | M | C,R | 149.94 | 13 | ++ | Aug. | – |
| 10 | 29 | F | R,D | >500 | >200 | ++++ | Sep. | + |
| 11 | 35 | F | R | 187.31 | 15.74 | +++ | Jul. | + |
| 12 | 27 | F | R | 210.94 | 12.73 | ++ | Aug. | – |
| 13 | 29 | M | C,R,D | >500 | 1.76 | ++++ | Jul. | + |
| 14 | 34 | M | AS,C,R | >500 | 2.27 | ++ | Jul. | – |
| 15 | 24 | M | C,R | >500 | 11.94 | ++ | Aug. | – |
| 16 | 31 | M | R | >500 | 100.12 | +++ | Aug. | – |
| 17 | 27 | M | C,R | >500 | >200 | ++ | Jul. | – |
| 18 | 34 | F | R | >500 | >200 | ++ | Sep. | – |
| 19 | 45 | F | R | 494.72 | >200 | ++ | Sep. | – |
| 20 | 19 | F | R | 189.11 | 62.14 | + | Jul. | – |
| 21 | 30 | M | AS,C,R,D | >500 | 13 | + | Jul. | – |
| 22 | 30 | M | R | >500 | >200 | – | Sep. | – |
| 23 | 32 | F | C,R,D | >500 | >200 | +++ | Aug. | – |
| 24 | 36 | M | R | >500 | >200 | +++ | Jun. | – |
| 25 | 23 | M | R | >500 | >200 | +++ | Sep. | – |
| 26 | 23 | F | R | >500 | >200 | + | Jun. | – |
| 27 | 25 | F | R | >500 | >200 | + | Jul. | – |
| 28 | 29 | F | C,R,D | 378.06 | 12.26 | +++ | Jul. | + |
| 29 | 28 | M | A,S,C,R | >500 | >200 | + | Aug. | – |
| 30 | 20 | M | R | >500 | >200 | +++ | Jul. | – |
| 31 | 34 | M | R | >500 | >200 | ++ | Jun. | – |
| 32 | 33 | M | R | >500 | >200 | +++ | Jul. | + |
| 33 | 32 | M | AS,C,R,D | >500 | >200 | +++ | Jul. | – |
| 34 | 37 | M | AS,C,R,D | >500 | 25.2 | + | Aug. | – |
| 35 | 30 | M | R | 433.54 | 46.69 | + | Jul. | – |
| 36 | 37 | M | C,R | >500 | >200 | +++ | Aug. | – |
| 37 | 39 | F | R | >500 | >200 | ++++ | Jul. | – |
| 38 | 34 | M | R,D | >500 | >200 | ++++ | Aug. | + |
| 39 | 36 | M | C,R | >500 | >200 | – | Jun. | + |
| 40 | 42 | F | AS,R,D | >500 | >200 | + | Sep. | – |
| 41 | 29 | M | AS,C,R,D | >500 | >200 | – | Jul. | + |
| 42 | 28 | M | R | 220.3 | 25.28 | +++ | Jul. | – |
| 43 | 36 | F | R | >500 | >200 | + | Aug. | – |
| 44 | 22 | F | R | >500 | >200 | +++ | Jul. | – |
| 45 | 20 | M | C,R | >500 | >200 | + | AYR | + |
| 46 | 26 | M | R | >500 | 43.72 | +++ | AYR | + |
| 47 | 29 | F | R | 20.1 | 0.39 | – | AYR | + |
| 48 | 40 | M | R | 40.71 | 0.35 | + | Aug. | – |
| 49 | 24 | M | R | >500 | 0.56 | + | Aug. | – |
| 50 | 28 | M | R | >500 | >200 | – | AYR | + |
| 51 | 49 | F | R | >500 | 0.63 | ++ | Jul. | – |
| 52 | 43 | F | R | >500 | 18.02 | + | Aug. | – |
| 53 | 27 | M | D,R | >500 | 0.38 | + | Jul. | – |
| 54 | 32 | M | R | >500 | 0.54 | ++ | Jul. | – |
| 55 | 32 | M | R | >500 | 62.46 | ++ | Nov. | – |
| 56 | 18 | F | R | >500 | 1.88 | +++ | Jul. | – |
| 57 | 35 | F | R | 36.64 | 0.68 | + | Aug. | – |
| 58 | 25 | M | R | >500 | >200 | +++ | Aug. | – |
| 59 | 30 | M | AS,C,R,D | >500 | >200 | +++ | Jun. | – |
| 60 | 28 | M | R | >500 | 1.75 | – | Aug. | – |
| 61 | 34 | M | C,R | 473.2 | 0.44 | – | Aug. | – |
| 62 | 29 | M | R | >500 | >200 | ++ | Aug. | – |
| 63 | 35 | M | R | >500 | >200 | ++ | Sep. | – |
| 64 | 32 | M | C,R | >500 | 0.37 | ++ | Aug. | – |
| 65 | 31 | M | C,R | >500 | >200 | + | Aug. | – |
| 66 | 47 | M | AS,C,R | >500 | >200 | ++ | Aug. | – |
| 67 | 36 | M | C,R | >500 | >200 | ++ | Jul. | – |
| 68 | 32 | M | C,R | >500 | >200 | ++++ | Jul. | + |
| 69 | 24 | M | R | >500 | >200 | ++++ | AYR | + |
| 70 | 33 | M | C,R | >500 | 21.98 | ++ | Aug. | – |
| 71 | 22 | M | R,D | >500 | >200 | ++++ | Aug. | + |
| 72 | 26 | M | C,R | 499.5 | 0.35 | ++++ | Nov. | – |
| 73 | 29 | M | R,D | >500 | >200 | – | Oct. | – |
| 74 | 31 | F | D,R | >500 | 0.4 | – | Sep. | – |
| 75 | 56 | F | R | >500 | 37.94 | – | Oct. | – |
| 76 | 29 | M | R | >500 | 24.38 | + | Jul. | – |
| 77 | 29 | M | R | >500 | >200 | +++ | Jun. | + |
a. Symptoms abbreviations: AS, asthma; C, conjunctivitis; R, rhinitis; D, Dermatosis: Eczema or urticaria.
b. In vitro diagnosis of total IgE assay (IU/ml) by Reversed-enzyme allergo-sorbent test (REAST). (BioLISA Allergy Reagent Kit, HOB Biotech, China).
c. Serum specific IgE assays against Artemisia vulgaris (IU/ml) by REAST (BioLISA Allergy Reagent Kit, HOB Biotech, China).
d. Skin prick testing (SPT) with whole Artemisia pollen extract (Allergo™) on the volar surface of the forearm. SI (skin index) = wheal diameter of extract (mm)/wheal diameter of histamine (mm), SI<0.25 is negative; a positive skin reaction was defined as a mean wheal diameter≥3 mm, meanwhile 0.3≤SI<0.5: +, 0.5≤SI<1: ++, 1≤SI<2: +++, SI≥2: ++++.
e. Onset time of patient’s symptoms; AYR: all year round.
f. IB: Immunoblot results, IgE immunoblot results for ArtCaM; +: serum IgE was positive to ArtCaM; -: negative result.
Figure 1Mass spectrometry and peptide matches. (A) Identification process of Artemisia calmodulin (ArtCaM). (B) MS basepeak of proteins samples from A.sieversiana and A.lavandulifolia pulled down by patients’ IgE. (C) Mass spectra fingerprint of marker peptide “ADQLDDQSEFK”. (D) Nature protein sequence, verified peptides by mass spectra fingerprint showed in red.
Identification of known allergens from Artemisia pollen.
| Protein names | Protein IDs | Sequence coverage [%] | Sequence length | Score |
|---|---|---|---|---|
| Non-specific lipid-transfer protein | P0C088 | 43.5 | 115 | 121.64 |
| Putative galactose oxidase | A0A2H4HHX3 | 19 | 595 | 78.904 |
| Profilin-1 | Q8H2C9 | 14.3 | 133 | 57.497 |
| Sarcoplasmic calcium-binding protein | P86909 | 100 | 8 | 41.052 |
| Putative galactose oxidase | A0A2H4HI03 | 11.8 | 594 | 40.362 |
| Non-specific lipid-transfer protein | A0A1W5LDC9 | 43.1 | 116 | 38.006 |
| Art v 2.01 allergen | A0A2L1DGY9 | 18.4 | 163 | 29.548 |
| Non-specific lipid-transfer protein | A0A1W5LDB8 | 28.4 | 116 | 27.285 |
| Sarcoplasmic calcium-binding protein | P86909 | 100 | 8 | 22.396 |
| Major pollen allergen Art v 1-like protein | A0A0H3U1U3 | 13.9 | 108 | 13.074 |
| Arginine kinase Lit v 2.0101 | Q004B5 | 3.7 | 356 | 10.47 |
| antigen 5 like allergen Cul n 1 | A0A6P8KJK7 | 9.4 | 255 | 9.8882 |
| Polcalcin Che a 3 | Q84V36 | 12.8 | 86 | 6.6732 |
| Art si 2.0101 allergen | A0A2L1DGX9 | 6.7 | 163 | 6.6515 |
| Major allergen Pru av 1 | A0A0B2PZ93 | 6.3 | 158 | 6.4642 |
| Putative Ole e 13.01 allergen | A0A5B6Z6D0 | 5 | 484 | 6.3204 |
| Pectate lyase 3 | P28744 | 2.8 | 392 | 6.1919 |
| Minor allergen Alt a 7-like | A0A7J7C8Z2 | 5.4 | 203 | 6.0696 |
| Allergen V5/Tpx-1 family protein | A0A0R2ZEX5 | 14.8 | 283 | 6.0625 |
| Allergen V5/Tpx-1 | A0A0K9F466 | 6.2 | 373 | 5.8488 |
| Allergen V5/Tpx-1 related | A0A095AUZ4 | 6.9 | 216 | 5.8317 |
| CRISP/Allergen/PR-1-like Protein | A0A139WGI3 | 5.1 | 313 | 5.8235 |
Figure 2IgE Immunoblot analyses of recombinant ArtCaM. (A) Immunoblots of individual serum with Artemisia calmodulin (ArtCaM). (B) The onset time of ArtCaM- or ArtCaM+ patients’ symptoms, P<0.0001. (C) Correlation between SPT and Immunoblot results, P<0.001. (D) ArtCaM-positive patients’TNSS were significant higher than ArtCaM-negative patients. ****P<0.0001. (E) RQLQ were significant higher than ArtCaM-negative patients. ****P<0.0001.
Figure 3ArtCaM induced DCs phenotypic maturation. (A) Statistical diagrams of flow cytometry. The column chart shows the Median Fluorescence Intensity (MFI) by flow cytometryrelative folds of CD80, CD86, and HLA-DR (mean ± SD, n=3) under ArtCaM (0, 50, 100, 200 nM). nsP>0.1; *P<0.5; **P<0.01; ***P<0.001; ****P<0.0001. (B) Fluorescence intensity changes of CD80, CD86, and HLA-DR under ArtCaM (0, 50, 100, 200 nM) and LPS(2ug/ml). (C) Statistical diagrams of flow cytometry. The column chart shows the Median Fluorescence Intensity by flow cytometry relative folds of CD80, CD86, and HLA-DR (mean ± SD, n=3) under ArtCaM, pIgE, ArtCaM+pIgE in both cDCs and pDCs. (D) Statistical diagrams of flow cytometry. The column chart shows the fluorescence intensity changes of CD80, CD86, and HLA-DR (mean ± SD, n=3) under control, ArtCaM200nM, 2-APB, ArtCaM200nM+2-APB. 10μM 2-APB significantly reduced the phenotypic maturation of DCs indicated by the CD80, CD86 and HLA-DR levels. (E) Phenotype of cDCs under ArtCaM, pIgE, ArtCaM+pIgE, and LPS treatment shows by expression of the antigens (CD40, CD209, CD80, CD86, HLA-DR) on cDCs. (F) Phenotype of pDCs under ArtCaM, pIgE, ArtCaM+pIgE, and LPS treatment shows by expression of the antigens (CD40, CD209, CD80, CD86, HLA-DR) on pDCs.
Figure 4ArtCaM/IgE directed DCs priming Th polarization. (A) Schematic diagram of Th polarization. (B–H) Cytokines’ concentration secreted by each individual DCs detected by ELISA (mean ± SD, n=3-12). nsP>0.1; *P<0.5; ** P<0.01; ***P<0.001.
Figure 6Proposed model of an allergenic plant calmodulin from Artemisia argyi pollen primes human DCs leading to Th2 polarization.
Figure 5Biological activity of ArtCaM present in DCs. (A) ArtCaM in the culture medium was sufficient to increase of intracellular IP3 (**P<0.01). (B) Ca2+ probe Fluo-4 AM was utilized to monitor the intracellular Ca2+ concentration. Fluorescence intensity was measured using laser microscope. Time-lapse in same visual field every 30 seconds which exhibited Ca2+ spikes in individual cells during 15 min. DCs exhibited characteristically oscillatory Ca2+ spikes located nearby the nucleus for a period of 2 min. (C) Fluorescence intensity changes of four individual cells in control groups, ArtCaM groups, and ArtCaM+2-APB groups.10μM 2-APB significantly reduced the changes of fluorescence intensity. (D) ArtCaM induced increasing of Ca2+ signal in human peripheral blood DCs detected by flow cytometer. (E) ArtCaM induced phosphorylation of Erk1/2, NFATC2, and CaMKII in a dose-dependent manner in minutes. (F) IP3R inhibitor 2-APB 10μM significantly reduced the phosphorylation levels of NFATC2, CaMKII, but not Erk1/2 phosphorylation. (G) ArtCaM-specific IgE blocked the Erk signal pathway but had no effects on NFATC2 and CaMKII detected by immunoblotting.